The Challenge of Incorporating High-Cost Technologies: An Analysis of PCSK9 Inhibitors.
作者信息
Marcolino Miriam Allein Zago, Decker Sérgio Renato da Rosa, Bertoldi Eduardo Gehling, Polanczyk Carisi A
机构信息
Instituto de Avaliação de Tecnologia em Saúde - INCT/IATS, Universidade Federal do Rio Grande do Sul, RS - Brasil.
Programa de Pós-Graduação em Epidemiologia - Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS - Brasil.
出版信息
Arq Bras Cardiol. 2021 Nov;117(5):997-998. doi: 10.36660/abc.20210840.
Abstract
摘要
相似文献
1
The Challenge of Incorporating High-Cost Technologies: An Analysis of PCSK9 Inhibitors.纳入高成本技术的挑战：PCSK9抑制剂分析
Arq Bras Cardiol. 2021 Nov;117(5):997-998. doi: 10.36660/abc.20210840.
2
Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol.涉及 PCSK9 抑制剂降低 LDL-胆固醇的结果、可及性和成本问题。
Drugs. 2018 Mar;78(3):287-291. doi: 10.1007/s40265-018-0867-9.
3
Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂的多效性作用？
Circulation. 2016 Nov 29;134(22):1695-1696. doi: 10.1161/CIRCULATIONAHA.116.023687.
4
[Not Available].[无可用内容]。
MMW Fortschr Med. 2024 May;166(8):18. doi: 10.1007/s15006-024-3912-5.
5
Proprotein Convertase Subtilisin Kexin 9 Inhibitors.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂
Cardiol Clin. 2018 May;36(2):241-256. doi: 10.1016/j.ccl.2017.12.006.
6
Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂的成本效益：模型验证
JAMA Cardiol. 2017 Dec 1;2(12):1298-1299. doi: 10.1001/jamacardio.2017.3656.
7
An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.前蛋白转化酶枯草溶菌素 9 抑制剂的临床开发进展：降低低密度脂蛋白胆固醇的新型治疗药物
Cardiovasc Ther. 2014 Apr;32(2):82-8. doi: 10.1111/1755-5922.12056.
8
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.PCSK9（前蛋白转化酶枯草溶菌素 9）抑制剂潜在长期靶标副作用的遗传评估。
Circ Genom Precis Med. 2019 Jan;12(1):e002196. doi: 10.1161/CIRCGEN.118.002196.
9
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.前蛋白转化酶枯草溶菌素 9（PCSK9）抑制与降脂治疗的未来。
Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1.
10
Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.前蛋白转化酶枯草杆菌蛋白酶/克新9型抑制剂：对心血管动脉粥样硬化病理生理学的新见解及其治疗意义。
Arch Cardiovasc Dis. 2019 Aug-Sep;112(8-9):455-458. doi: 10.1016/j.acvd.2019.06.003. Epub 2019 Sep 5.
本文引用的文献
1
Cost-Effectiveness Analysis of Evolocumab Therapy in Patients at High Risk of Cardiovascular Events in the Context of the Brazilian Unified Health System.巴西统一卫生系统背景下高心血管事件风险患者依洛尤单抗治疗的成本效果分析。
Arq Bras Cardiol. 2021 Nov;117(5):988-996. doi: 10.36660/abc.20200690.
2
How to live to 100 before developing clinical coronary artery disease: a suggestion.如何在患临床冠状动脉疾病之前活到100岁：一项建议。
Eur Heart J. 2022 Jan 31;43(4):249-250. doi: 10.1093/eurheartj/ehab532.
3
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.PCSK9 单克隆抗体在高心血管风险患者中的疗效和安全性：32 项随机对照试验的更新系统评价和荟萃分析。
Adv Ther. 2020 Apr;37(4):1496-1521. doi: 10.1007/s12325-020-01259-4. Epub 2020 Feb 27.
4
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.PCSK9 抑制剂在心血管疾病中的成本效益分析：系统评价。
Heart Fail Rev. 2020 Nov;25(6):1077-1088. doi: 10.1007/s10741-019-09874-2.
5
The cost of stroke in a public hospital in Brazil: a one-year prospective study.巴西一家公立医院中风的成本：一项为期一年的前瞻性研究。
Arq Neuropsiquiatr. 2019 Jul 15;77(6):404-411. doi: 10.1590/0004-282X20190059.
6
PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice.PCSK9 抑制剂：临床相关性、分子机制及临床实践中的安全性。
Arq Bras Cardiol. 2019 Apr;112(4):453-460. doi: 10.5935/abc.20190029. Epub 2019 Feb 28.
7
Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在心血管风险高和极高的患者中的应用指征
Arq Bras Cardiol. 2018 Jul;111(1):104-108. doi: 10.5935/abc.20180133.
8
Coronary Artery Bypass Graft Surgery Cost Coverage by the Brazilian Unified Health System (SUS).巴西统一卫生系统（SUS）对冠状动脉旁路移植手术费用的覆盖情况。
Braz J Cardiovasc Surg. 2017 Jul-Aug;32(4):253-259. doi: 10.21470/1678-9741-2016-0069.
9
PCSK9 Inhibition to Reduce Cardiovascular Events.前蛋白转化酶枯草溶菌素9（PCSK9）抑制作用以降低心血管事件
N Engl J Med. 2017 May 4;376(18):1790-1791. doi: 10.1056/NEJMe1703138. Epub 2017 Mar 17.
10
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
Zotero 插件